Comparison
Lucid Bio is the firm we benchmark closest on positioning: bespoke biotech intelligence, small senior-led team, content-marketing-led visibility. The two outfits look adjacent at first read. The differences live in therapeutic-area focus, published sample work, and how citation discipline is operationalised inside each deliverable. This page lays out where each fits.
Lucid Bio is a boutique biotech intelligence outfit offering bespoke competitive intelligence, landscape analyses, and strategic research for biotech and biopharma clients. Public presence is content-marketing-led (blog posts, founder thought leadership, social channels). Therapeutic area coverage is broad across biotech (oncology, rare disease, gene/cell therapy, neuroscience, autoimmune). Sample deliverables are not published as downloadable PDFs on the public site at time of writing; engagements are scoped privately with each client. Pricing is not publicly disclosed.
Delvant is a bounded custom-intelligence service. Each engagement starts from one or two specific questions a buyer cannot answer with a templated report, scopes the comparator set, runs a fresh search against locked anchor sources (ClinicalTrials.gov, EMA, FDA, PubMed, EHA, ASH, EULAR, AACR, ASCO, ESMO), tags every claim by provenance tier (Sourced, Inferred, Opinion, Hedged), and ships a 10-30 page deliverable in 5-15 business days. Tier 1 briefs start at EUR 3,500. Tier 2 strategic dossiers run EUR 12,000-35,000. A full T2 demonstrator is published openly with per-claim provenance tags visible.
| Dimension | Lucid Bio | Delvant |
|---|---|---|
| Product shape | Bespoke competitive intelligence and landscape engagements. Scoped per client. Format varies. | Bounded custom-scoped deliverable. One-to-three commissioned questions per engagement. Fixed 10-30 page PDF + slide-deck format. |
| Therapeutic area scope | Broad. Biotech-wide: oncology, rare disease, gene/cell therapy, neuroscience, autoimmune. | Narrow by design. Core: rare hematology, immune cytopenias (ITP, AIHA, HDFN), plasma-derived therapeutics. Adjacent: rare oncology, IgG autoimmune, transplant. |
| Citation discipline | Sources cited at deliverable level. Per-claim source mapping not exposed publicly. | Per-claim tier tags (Sourced / Inferred / Opinion / Hedged) visible inline on every assertion. Every Sourced claim re-verified at the cited URL during Gate A pass. |
| Public sample deliverables | Content-marketing led: blog posts, articles, social posts, founder commentary. Full sample deliverables not published as PDFs at time of review. | Full T2 demonstrator (ITP TPO-RA vs FcRn) published openly with per-claim provenance tagging visible. T1, T2, T3, T4 deck-format previews also published. |
| Methodology transparency | Methodology described qualitatively in client conversations and content posts. | Pre-delivery gate methodology published openly: Gate A (deep-research re-verification), Gate B (LLM-council adversarial review), Gate C (peer pass on T1, additional passes on T2). Originality.ai plagiarism scan on every paid deliverable. |
| Turnaround | Scoped per engagement. Public information does not list a fixed turnaround commitment. | 5 business days (T1). 10-15 business days (T2). Fixed schedule, no rush-fee compression. |
| Indicative price (public) | Not publicly disclosed. | From EUR 3,500 (T1, 1 question, 10-15 pages). EUR 12,000-35,000 (T2, 2-3 questions, 20-30 pages). |
| Team shape | Founder-led boutique with senior bench. | Single accountable owner per engagement (founder-led at current stage). External peer pass + LLM-council adversarial review built into Gates A/B/C. |
| AI methodology | Public disclosure of AI use in workflow not detailed at time of review. | AI-assisted retrieval and synthesis under documented human oversight. Gate A re-verifies every Sourced claim; Gate B runs LLM-council adversarial review. EU AI Act Article 4 deployer posture disclosed. |
| Buyer fit | Biotech founders, CSOs, CBOs needing landscape work or competitive intelligence across broad therapy areas. | Medical affairs, BD search-and-evaluation, small-biotech CMOs, life-sciences analysts who need a single sharp comparator answer with audit-grade citation, fast, in our core TAs. |
Delvant is not a broad biotech intelligence shop. If your question sits in oncology-wide, neuroscience, or gene/cell therapy, Lucid Bio or another biotech-focused boutique will have deeper coverage. We deliberately stay narrow because the per-claim provenance discipline scales better inside a tight therapeutic frame.
Delvant is also not a strategy consultancy. If your question requires 6-12 weeks of senior advisory time, integrated primary research at scale, and a signed strategic recommendation, you should commission Putnam Associates, Trinity, L.E.K. Life Sciences, Health Advances, ZS, or IQVIA Consulting. Delvant covers the gap between bespoke biotech intelligence outfits and full consulting engagements: bounded custom work at 5-15 business day turnaround, EUR 3,500-35,000, narrow TA, audit-grade citation visible per claim.
30-minute scoping call. We will tell you whether your question fits Delvant's narrow TA wedge, or whether a broader biotech-focused boutique like Lucid Bio is the better starting point. Honest fit calls only.
Book a scoping call See engagement tiers